Sponsor Dossier
Gilead Sciences
Sponsor Dossier for Gilead Sciences. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AMBISOME
- Brand: BIKTARVY
- Brand: DESCOVY
- Brand: EPCLUSA
- Brand: EVIPLERA
- Brand: GENVOYA
- Brand: HARVONI
- Brand: HEPCLUDEX
About
Gilead Sciences is an Australian Private Company with ABN 71 072 611 708, registered in Victoria. The entity is currently active.
Portfolio
Gilead Sciences has 21 brands on the ARTG, with 20 indexable brands and 20 brands with Product Information on file. The portfolio includes 2 brands with at least one PBS-listed item, 15 brands with PBAC outcomes on record, and 13 brands with AusPARs on record. Notable brands include AMBISOME, BIKTARVY, DESCOVY, EPCLUSA, EVIPLERA, GENVOYA, HARVONI, HEPCLUDEX, LIVDELZI, ODEFSEY and STRIBILD.
Therapeutic focus
— Infectious Disease: 17 brands — Oncology: 2 brands — Gastroenterology: 1 brand — Hepatology: 1 brand
PBS footprint
Two of Gilead Sciences' brands are PBS-listed, with the portfolio's latest PBS schedule date being 1 May 2026.
Regulatory activity
Gilead Sciences' most recent PBAC outcome was on 1 December 2025, with 15 brands holding PBAC outcomes on record. The most recent AusPAR was issued on 22 July 2024, with 13 brands holding AusPARs on record.